Merck (MRK)
114.90
-3.30 (2.79%)
Upcoming Events
Latest Headlines
German government to drop variable drug discounting plans - Reuters
June 15, 2026 6:08 AM - StreetInsider
FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer
June 12, 2026 4:10 PM - StreetInsider
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Ce
June 12, 2026 4:10 PM - BizWire
Merck Animal Health to acquire poultry technology firm TARGAN
June 11, 2026 6:45 AM - StreetInsider
Merck Animal Health to Acquire TARGAN
June 11, 2026 6:45 AM - BizWire
Gilead and Merck announce successful HIV treatment trial results
June 8, 2026 4:35 PM - StreetInsider
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
June 8, 2026 4:35 PM - BizWire
Merck and Gilead discontinue lung cancer drug combination trial
June 8, 2026 4:30 PM - StreetInsider
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
June 8, 2026 4:30 PM - BizWire
MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & Business Development
June 8, 2026 8:00 AM - Globe NewsWire
Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
June 3, 2026 9:01 AM - PR NewsWire
Form 4 Merck & Co., Inc. For: May 29 Filed by: Warden Kathy J
June 2, 2026 4:15 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Karsanbhai Surendralal Lanca
June 2, 2026 3:32 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Coe Mary Ellen
June 2, 2026 2:27 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: THULIN INGE G
June 2, 2026 2:21 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Seidman Christine E
June 2, 2026 2:20 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: RUSSO PATRICIA F
June 2, 2026 2:18 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Rothman Paul
June 2, 2026 2:14 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Mayo Stephen
June 2, 2026 2:11 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: LAVIZZO-MOUREY RISA J
June 2, 2026 2:10 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: GLOCER THOMAS H
June 2, 2026 2:06 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: Craig Pamela J.
June 2, 2026 2:03 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 29 Filed by: BAKER DOUGLAS M JR
June 2, 2026 1:57 PM - SEC Filing
Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald
June 2, 2026 7:23 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Merck (MRK)
June 2, 2026 6:48 AM - StreetInsider
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 2, 2026 6:45 AM - BizWire
Moderna and Merck report sustained melanoma treatment benefits at 5 years
June 1, 2026 8:01 AM - StreetInsider
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
June 1, 2026 8:01 AM - StreetInsider
Form SD Merck & Co., Inc.
May 29, 2026 1:24 PM - SEC Filing
FDA grants breakthrough therapy designation to Merck's KRAS G12C inhibitor
May 29, 2026 6:49 AM - StreetInsider
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
May 29, 2026 6:45 AM - BizWire
Form 8-K Merck & Co., Inc. For: May 26
May 28, 2026 5:02 PM - SEC Filing
Merck to Participate in the Jefferies Global Healthcare Conference
May 28, 2026 6:45 AM - BizWire
Merck (MRK) Declares $0.85 Quarterly Dividend; 2.8% Yield
May 26, 2026 1:28 PM - StreetInsider
Merck Announces Third-Quarter 2026 Dividend
May 26, 2026 1:28 PM - BizWire
Form 8-K Merck & Co., Inc. For: May 22
May 22, 2026 4:21 PM - SEC Filing
China holds roundtable with over 50 foreign pharmaceutical firms
May 22, 2026 9:54 AM - StreetInsider
China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
May 22, 2026 9:24 AM - StreetInsider
Merck receives EU committee approval recommendation for bladder cancer drug combo
May 22, 2026 7:55 AM - StreetInsider
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasiv
May 22, 2026 7:55 AM - BizWire
Merck KGaA begins phase 3 trial for colorectal cancer drug
May 21, 2026 8:01 AM - StreetInsider
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer
May 21, 2026 8:00 AM - BizWire
Form 424B5 Merck & Co., Inc.
May 20, 2026 4:24 PM - SEC Filing
Synergis Software Launches Adept Cloud, a Cloud-Native Engineering Document Management Platform Built for Asset-Intensive Industries
May 20, 2026 11:02 AM - PR NewsWire
Form FWP Merck & Co., Inc. Filed by: Merck & Co., Inc.
May 19, 2026 6:02 AM - SEC Filing
Trump to unveil more discounted prescription drug options - CNBC
May 18, 2026 10:59 AM - StreetInsider
Form 424B5 Merck & Co., Inc.
May 18, 2026 8:14 AM - SEC Filing
Merck endometrial cancer drug meets survival goals in phase 3 trial
May 18, 2026 6:46 AM - StreetInsider
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or R
May 18, 2026 6:45 AM - BizWire
Form 13F-HR Merck & Co., Inc. For: Mar 31
May 13, 2026 4:07 PM - SEC Filing
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026 8:33 AM - StreetInsider
Merck to present oncology data across 25 cancer types at ASCO 2026
May 12, 2026 6:45 AM - StreetInsider
Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research at ASCO 2026
May 12, 2026 6:45 AM - BizWire
Merck publishes synthesis method for oral PCSK9 inhibitor in Science
May 7, 2026 2:12 PM - StreetInsider
Merck Scientists Publish Landmark Paper on Novel Method for Large-Scale Biocatalytic Synthesis of Investigational Oral PCSK9 Inhibitor, Enlicitide Decanoate
May 7, 2026 2:05 PM - BizWire
Form 4 Merck & Co., Inc. For: May 05 Filed by: Zachary Jennifer
May 7, 2026 12:18 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Williams David Michael
May 7, 2026 12:14 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Litchfield Caroline
May 7, 2026 12:10 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Li Dean Y
May 7, 2026 12:07 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Larson Betty D
May 7, 2026 12:03 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: DeLuca Richard R.
May 7, 2026 11:57 AM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Davis Robert M
May 7, 2026 11:53 AM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Foard Brian
May 7, 2026 11:48 AM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Maraldo David R.
May 7, 2026 11:46 AM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Oosthuizen Johannes Jacobus
May 7, 2026 11:43 AM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Smart Dalton E. III
May 7, 2026 11:39 AM - SEC Filing
Form 4 Merck & Co., Inc. For: May 05 Filed by: Guindo Chirfi
May 7, 2026 11:37 AM - SEC Filing
MilliporeSigma Becomes Sole Testing Provider for Genetix Biotherapeutics’ FDA-Approved Gene Therapies
May 7, 2026 8:00 AM - Globe NewsWire
Merck Animal Health Selects Salesforce’s Agentforce Life Sciences for Customer Engagement to Transform Animal Care and Enhance Support Experiences for Employees
May 6, 2026 9:00 AM - BizWire
Citi Reinstates Merck (MRK) at Neutral
May 6, 2026 5:01 AM - StreetInsider
Form 4 Merck & Co., Inc. For: May 02 Filed by: Smart Dalton E. III
May 5, 2026 1:52 PM - SEC Filing
Form 4 Merck & Co., Inc. For: May 02 Filed by: Maraldo David R.
May 5, 2026 1:47 PM - SEC Filing
Form 3/A Merck & Co., Inc. For: May 01 Filed by: Maraldo David R.
May 5, 2026 1:08 PM - SEC Filing
Merck completes $5.8 billion acquisition of Terns Pharmaceuticals
May 5, 2026 8:45 AM - StreetInsider
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
May 5, 2026 8:45 AM - BizWire
Form 3 Merck & Co., Inc. For: May 01 Filed by: Maraldo David R.
May 4, 2026 6:28 PM - SEC Filing
Form 10-Q Merck & Co., Inc. For: Mar 31
May 4, 2026 4:11 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Guindo Chirfi
May 1, 2026 6:54 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Chattopadhyay Sanat
May 1, 2026 6:32 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: DeLuca Richard R.
May 1, 2026 6:20 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Williams David Michael
May 1, 2026 5:57 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Smart Dalton E. III
May 1, 2026 5:56 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Li Dean Y
May 1, 2026 5:45 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Zachary Jennifer
May 1, 2026 5:44 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Larson Betty D
May 1, 2026 5:43 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Litchfield Caroline
May 1, 2026 5:40 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Davis Robert M
May 1, 2026 5:38 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Apr 29 Filed by: Oosthuizen Johannes Jacobus
May 1, 2026 5:35 PM - SEC Filing
Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid Crisis
May 1, 2026 1:15 PM - BizWire
Merck (MRK) PT Lowered to $130 at BofA Securities
May 1, 2026 10:53 AM - StreetInsider
Merck (MRK) PT Raised to $112 at Morgan Stanley
May 1, 2026 9:13 AM - StreetInsider
Merck (MRK) PT Lowered to $145 at Wells Fargo
May 1, 2026 7:53 AM - StreetInsider
Form SCHEDULE 13G Merck & Co., Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 11:45 AM - SEC Filing
Merck KGaA begins phase 3 lupus skin treatment trial
April 30, 2026 8:05 AM - StreetInsider
Merck KGaA, Darmstadt, Germany, Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
April 30, 2026 8:05 AM - BizWire
Form 8-K Merck & Co., Inc. For: Apr 30
April 30, 2026 6:53 AM - SEC Filing
Merck beats estimates on strong oncology sales; shares up 4% in pre-market trade
April 30, 2026 6:45 AM - StreetInsider
Merck (MRK) Tops Q1 EPS by 20c; offers guidance
April 30, 2026 6:32 AM - StreetInsider
Merck beats quarterly sales expectations as Keytruda fuels growth
April 30, 2026 6:31 AM - StreetInsider
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones
April 30, 2026 6:30 AM - BizWire
Merck (MRK) call put ratio 1.4 calls to 1 put into quarter results
April 29, 2026 11:21 AM - StreetInsider
Merck (MRK) call put ratio 1 call to 1.4 puts into quarter results
April 29, 2026 4:41 AM - StreetInsider
Merck’s Playing with Heart Program Teams Up With Professional Baseball Clubs and Baseball Legends to Help Raise Awareness About LDL-C, Called “Bad” Cholesterol, and How It May Impact the Risk of
April 28, 2026 6:45 AM - BizWire
Guggenheim Reiterates Buy Rating on Merck (MRK)
April 27, 2026 6:42 AM - StreetInsider
AI is starting to impact the pharma sector — These 2 stocks are seen as NT winners
April 25, 2026 4:00 AM - StreetInsider
Merck clears HSR waiting period for $53 per share Terns acquisition
April 24, 2026 6:45 AM - StreetInsider
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
April 24, 2026 6:45 AM - BizWire
Merck and Google Cloud announce $1 billion AI partnership
April 22, 2026 8:01 AM - StreetInsider
Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation
April 22, 2026 8:00 AM - PR NewsWire
FDA approves Merck's IDVYNSO for HIV-1 treatment switch
April 21, 2026 2:11 PM - StreetInsider
FDA Approves Merck’s Once-Daily IDVYNSO™ (doravirine/islatravir)
April 21, 2026 2:11 PM - BizWire
Merck and Eisai report failed kidney cancer drug trial results
April 21, 2026 8:37 AM - StreetInsider
MilliporeSigma Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
April 21, 2026 8:01 AM - Globe NewsWire
Merck and Eisai trial for kidney cancer combination therapy fails endpoints
April 21, 2026 6:45 AM - StreetInsider
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21, 2026 6:45 AM - BizWire
UBS Reiterates Buy Rating on Merck (MRK)
April 20, 2026 9:51 AM - StreetInsider
FDA grants priority review for Merck's KEYTRUDA combinations in bladder cancer
April 20, 2026 6:48 AM - StreetInsider
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Pat
April 20, 2026 6:48 AM - BizWire
European Commission approves Merck's ENFLONSIA for RSV prevention in infants
April 17, 2026 7:50 AM - StreetInsider
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
April 17, 2026 7:49 AM - BizWire
Amazon cloud unit launches AI tool to accelerate drug discovery
April 14, 2026 10:35 AM - StreetInsider
Merck (MRK) PT Raised to $145 at UBS
April 13, 2026 8:54 AM - StreetInsider
FDA grants priority review to ifinatamab deruxtecan for lung cancer treatment
April 13, 2026 7:01 AM - StreetInsider
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Bas
April 13, 2026 7:00 AM - BizWire
Bernstein on US Pharma and Biotech: Who might buy whom?
April 13, 2026 5:52 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Merck (MRK)
April 9, 2026 7:09 AM - StreetInsider
Form ARS Merck & Co., Inc. For: Dec 31
April 8, 2026 4:32 PM - SEC Filing
Form DEFA14A Merck & Co., Inc.
April 8, 2026 4:29 PM - SEC Filing
Form DEF 14A Merck & Co., Inc. For: May 26
April 8, 2026 4:26 PM - SEC Filing
Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald As '26 Catalysts Already Credited
April 8, 2026 7:59 AM - StreetInsider
Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share
April 7, 2026 9:38 AM - StreetInsider
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
April 7, 2026 9:38 AM - BizWire
Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share
April 7, 2026 9:04 AM - StreetInsider
Merck (MRK) PT Raised to $135 at JPMorgan
April 6, 2026 7:45 AM - StreetInsider
Merck starts phase 2b/3 trial for eye disease drug MK-8748
April 2, 2026 6:50 AM - StreetInsider
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular
April 2, 2026 6:50 AM - BizWire
European Commission approves KEYTRUDA plus paclitaxel for ovarian cancer
April 2, 2026 6:45 AM - StreetInsider
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Receive
April 2, 2026 6:45 AM - BizWire
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Seidman Christine E
April 1, 2026 1:47 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: GLOCER THOMAS H
April 1, 2026 1:45 PM - SEC Filing
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Coe Mary Ellen
April 1, 2026 1:43 PM - SEC Filing
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30
April 1, 2026 7:00 AM - BizWire
Truist Securities Downgrades Terns Pharmaceuticals (TERN) to Hold
March 30, 2026 4:31 PM - StreetInsider
Merck (MRK) PT Raised to $138 at Jefferies
March 30, 2026 4:11 PM - StreetInsider
Merck drug shows superior cholesterol reduction in phase 3 trial
March 30, 2026 11:45 AM - StreetInsider
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies
March 30, 2026 11:45 AM - BizWire
Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald After Ph 2 CADENCE Data Release
March 30, 2026 9:32 AM - StreetInsider
Merck's WINREVAIR shows promise in heart failure trial
March 29, 2026 11:45 AM - StreetInsider
Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension
March 29, 2026 11:45 AM - BizWire
Form SCHEDULE 13G/A Merck & Co., Inc. Filed by: VANGUARD GROUP INC
March 27, 2026 10:32 AM - SEC Filing
Mizuho Downgrades Terns Pharmaceuticals (TERN) to Neutral on Merck acquisition
March 27, 2026 8:50 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Merck (MRK)
March 26, 2026 6:57 AM - StreetInsider
TD Cowen Downgrades Terns Pharmaceuticals (TERN) to Hold
March 25, 2026 4:09 PM - StreetInsider
BofA Securities on Merck (MRK): Terns adds to 2025 deals for de-risked drugs 'with growth expected during Keytrude LOE period'
March 25, 2026 12:22 PM - StreetInsider
Morgan Stanley on Merck (MRK): Terns acquisition 'encouraging and consistent with prior commentary'
March 25, 2026 10:30 AM - StreetInsider
H.C. Wainwright Downgrades Terns Pharmaceuticals (TERN) to Neutral
March 25, 2026 10:13 AM - StreetInsider
Barclays on Merck (MRK): Terns deal shows Merck shifting toward 'more diversified onco strategy'
March 25, 2026 9:34 AM - StreetInsider
Truist Securities stays Buy on Terns Pharmaceuticals (TERN) as Merck acquires 'for a steal'
March 25, 2026 8:12 AM - StreetInsider
Enliven Therapeutics stock surges 28% on Merck-Terns deal
March 25, 2026 7:39 AM - StreetInsider
Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal
March 25, 2026 7:02 AM - StreetInsider
Merck to acquire Terns Pharmaceuticals for $6.7 billion
March 25, 2026 6:45 AM - StreetInsider
Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
March 25, 2026 6:45 AM - BizWire
Merck (MRK) Nears $6b Deal To Buy Terns Pharma (TERN) - FT
March 24, 2026 9:20 PM - StreetInsider
FDA expands BRAVECTO QUANTUM label to cover two additional tick species
March 18, 2026 4:30 PM - StreetInsider
FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs
March 18, 2026 4:30 PM - BizWire
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Merck to present HPV vaccine data showing 14-18 year efficacy
March 17, 2026 6:50 AM - StreetInsider
Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026
March 17, 2026 6:50 AM - BizWire
Full Article List
